EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

A multicenter prospective cohort study evaluating impact of an active delisting strategy to enable kidney transplantation in wait-listed candidates with calculated Panel Reactive Antibody ≥ 99.9%

David Cucchiari, Esther Mancebo-Sierra, José Luis Caro, Maria Meneghini, María José Pérez-Saez, Beatriz Romero López, Dolores Redondo-Pachón, Carolt Arana, Oriol Bestard, Amado Andrés, Francesc Moreso, Marta Crespo und 2 weitere

Kidney International · 2025-11 · 108 (5) · 927-937

DOI: 10.1016/j.kint.2025.04.031 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Kidney International, 2025-11. Verfasst von David Cucchiari und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Kidney Transplantation, Hospital Clínic, Barcelona, Spain; Laboratori Experimental de Nefrologia I Trasplantament (LENIT…. Hauptthemen laut MEDLINE: Graft Rejection, HLA Antigens, Isoantibodies, Kidney Failure, Chronic. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: In kidney transplant candidates with calculated Panel Reactive Antibody (cPRA)≥99.9%, looking for perfect HLA compatibility may delay transplantation beyond a reasonable waiting time. However, the presence of preformed donor-specific antibody (DSA) does not always lead to antibody-mediated rejection. Here, we present the results of a delisting strategy for kidney transplant candidates with cPRA≥99.9% employed in four Spanish transplant centers May 2022-August 2023. METHODS: Briefly, HLA antigens were delisted if their mean fluorescence intensity (MFI) in current and historical samples was lower than 5,000, with the goal to decrease cPRA to ≤99.0%. If this first step was unsuccessful, HLA antibodies with an MFI under 10,000, or any MFI for anti-HLA-DP and anti-HLA-DRB3/4/5 were considered for delisting. Additional criteria included their 1/16 dilutions response and complement-binding activity (C3d or C1q), ideally avoiding antibodies targeting a cross-reactive epitope groups/eplet pattern and repeated mismatches with previous donors. RESULTS: In total, 48 patients underwent HLA-antigen delisting after a median 5.6 years on the waiting list, lowering their cPRA to 98.3%. Thirty (62.5%) patients received an acceptable donor offer 98[52-154] days after delisting, of which 18 (60.0%) had negative flow cytometry and complement-dependent cytotoxicity crossmatches and underwent direct transplantation without additional desensitization with the enzyme imlifidase. Among these, sixteen patients (83.3%) had at least one preformed DSA, with an immunodominant MFI of 7245[3857-18322]. In these patients, after one-year follow-up, antibody-mediated rejection occurred in seven cases (43.7%) and graft survival was 87.5%. CONCLUSIONS: Our study shows that careful antigen delisting enhances access to transplantation for patients with cPRA ≥99.9%. While this approach carries a significant risk of acute rejection, it is associated with reasonable short-term graft survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft RejectionHLA AntigensIsoantibodiesKidney Failure, ChronicKidney TransplantationWaiting ListsAdultFemaleHumansMaleMiddle AgedGraft SurvivalHistocompatibility TestingProspective StudiesSpainTime Factors

Stichwörter der Autor:innen

delistingdonor-specific antibodiesimlifidasekidney transplantationrejection

Substanzen

HLA AntigensIsoantibodies

Autor:innen und Institutionen

  • Department of Nephrology and Kidney Transplantation, Hospital Clínic, Barcelona, Spain; Laboratori Experimental de Nefrologia I Trasplantament (LENIT), Institut d'Investigacions Biomèdiques August Pi iSunyer (IDIBAPS),…
  • Immunology Department, University Hospital 12 de Octubre, Research Institute Hospital 12 Octubre (imas12), Madrid, Spain.
  • Immunology Department, Hospital Clínic, Barcelona, Spain.
  • Nephrology and Kidney Transplantation Department, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
  • REDinREN (RD16/0009/0013), Instituto de Salud Carlos III, Madrid, Spain; Department of Nephrology, Hospital del Mar, Institute Mar for Medical Research, Barcelona, Spain.
  • Nephrology Department, University Hospital 12 de Octubre, Research Institute Hospital 12 Octubre, Madrid, Spain.

Zitieren

APA

Cucchiari, D., Mancebo-Sierra, E., Caro, J. L., Meneghini, M., Pérez-Saez, M. J., López, B. R., Redondo-Pachón, D., Arana, C., Bestard, O., Andrés, A., Moreso, F., Crespo, M., Palou, E., & Diekmann, F. (2025). A multicenter prospective cohort study evaluating impact of an active delisting strategy to enable kidney transplantation in wait-listed candidates with calculated Panel Reactive Antibody ≥ 99.9%. Kidney International, 108(5), 927-937. https://doi.org/10.1016/j.kint.2025.04.031

Vancouver

Cucchiari D, Mancebo-Sierra E, Caro JL, Meneghini M, Pérez-Saez MJ, López BR, et al. A multicenter prospective cohort study evaluating impact of an active delisting strategy to enable kidney transplantation in wait-listed candidates with calculated Panel Reactive Antibody ≥ 99.9%. Kidney International. 2025;108(5):927-937. doi:10.1016/j.kint.2025.04.031

BibTeX
@article{Cucchiari2025,
  author = {Cucchiari, David and Mancebo-Sierra, Esther and Caro, José Luis and Meneghini, Maria and Pérez-Saez, María José and López, Beatriz Romero and Redondo-Pachón, Dolores and Arana, Carolt and Bestard, Oriol and Andrés, Amado and Moreso, Francesc and Crespo, Marta and Palou, Eduard and Diekmann, Fritz},
  title = {A multicenter prospective cohort study evaluating impact of an active delisting strategy to enable kidney transplantation in wait-listed candidates with calculated Panel Reactive Antibody ≥ 99.9%},
  journal = {Kidney International},
  year = {2025},
  volume = {108},
  number = {5},
  pages = {927--937},
  doi = {10.1016/j.kint.2025.04.031}
}
Kostenlos starten →